CSIMarket
 
Mural Oncology Plc  (MURA)
Other Ticker:  
 
 
Price: $4.7500 $-0.06 -1.247%
Day's High: $4.915 Week Perf: -8.48 %
Day's Low: $ 4.68 30 Day Perf: -4.62 %
Volume (M): 260 52 Wk High: $ 17.00
Volume (M$): $ 1,233 52 Wk Avg: $4.58
Open: $4.73 52 Wk Low: $3.23



 Market Capitalization (Millions $) 79
 Shares Outstanding (Millions) 17
 Employees -
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) 966
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 2

Mural Oncology Plc
Mural Oncology Plc is a pharmaceutical company specializing in the development of targeted cancer therapies. The company focuses on creating innovative treatments that address unmet medical needs in various types of cancer. Mural Oncology Plc utilizes advanced technologies and research methods to identify and develop potential drug candidates with high efficacy and minimal side effects. The company's mission is to improve the lives of cancer patients by providing them with effective and personalized treatment options. Mural Oncology Plc is committed to advancing the field of oncology and making significant contributions to cancer research.


   Company Address: 10 Earlsfort Terrace Dublin 2 0
   Company Phone Number: 1-905-8020   Stock Exchange / Ticker: NASDAQ MURA
   MURA is expected to report next financial results on December 13, 2024.


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Shares

Mural Oncology Fuels Talent Acquisition with Inducement Grants, Bolstering Innovative Cancer Therapies

Published Mon, Mar 4 2024 9:15 PM UTC

Mural Oncology Grants Inducement Options and Restricted Stock Units to Newly Hired Employees
DUBLIN, Ireland ?? March 04, 2024 - Mural Oncology plc (Nasdaq: MURA), a renowned clinical-stage immuno-oncology company specializing in immune cell modulation and protein engineering, has recently made an important announcement regarding inducement grants under Nasdaq Listing Ru...

Clinical Study

Unlocking the Future of Cancer Treatment: Mural Oncology Enhances Late-Stage Trials with Unprecedented Clinical Relevance

Published Mon, Jan 8 2024 12:00 PM UTC

Mural Oncology Revolutionizes Late-Stage Clinical Trials: Maximizing Clinical Relevance with ARTISTRY-6 and ARTISTRY-7 In a groundbreaking development, Mural Oncology has unveiled strategic enhancements to their late-stage clinical trials, ARTISTRY-6 and ARTISTRY-7. These trials, focusing on the experimental drug nemvaleukin, aim to produce more clinically meaningful data, r...






 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com